"Cannabidiol Significantly Reduces Seizures in Patients with Severe Form of Epilepsy"

Researchers provide further evidence that the cannabis compound, CBD, is effective at reducing seizures in people with epilepsy. The new study reveals CBD significantly reduced seizures in people with Lennox-Gastaut syndrome. Previously, the researchers demonstrated CBD was effective at seizure control in Dravet syndrome.

Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” and has been an increasing focus of medical research, was shown in a new large-scale, randomized, controlled trial to significantly reduce the number of dangerous seizures in patients with a severe form of epilepsy called Lennox–Gastaut syndrome.

"Cannabidiol could help deliver medications to the brain"

Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging from anxiety to epilepsy.

Although much more research is needed to verify these claims, scientists have now shown that CBD could have a different use as a "Trojan horse": helping slip medications across the blood-brain barrier (BBB).

The researchers report their results in the ACS journal Molecular Pharmaceutics.

The BBB consists of a layer of tightly linked cells that line capillaries in the brain, preventing substances from exiting the blood and entering the brain. However, the BBB does permit some molecules to pass, such as glucose and certain amino acids and neurotransmitters. For example, a class of neurotransmitters called endocannabinoids bind to proteins called cannabinoid receptors in the BBB, and the receptors help transport the molecules across the barrier and into the brain.

"Evidence for Therapeutic Properties of CBD/THC in Alzheimer's Disease"

Alzheimer's Disease (AD) is a debilitating neurodegenerative disease that is characterized by cognitive decline.

It is the most common form of dementia,accounting for over 60% of cases and affecting over 33 million people worldwide.


Unfortunately the current approved AD treatments only provide limited therapeutic benefits.

There are four approved drugs available, but unfortunately, all of them have been associated with adverse effects. Acetylcholinesterase inhibitors may cause nausea, vomiting, diarrhea and weight loss, while memantine is known to cause hallucinations, dizziness and fatigue.Furthermore, none of these treatments prevent or reverse the progression of the disease but rather they treat the disease symptoms with limited efficacy

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid that has demonstrated neuroprotective, anti-inflammatory and antioxidant properties. It is investigated as a potential multifunctional treatment option for AD.

Here, we summarize the current status quo of effects of CBD in established pharmacological and transgenic animal models for AD.The phytocannabinoid cannabidiol (CBD) is a prime candidate for this new treatment strategy.

The in vivo therapeutic potential of CBD in AD has not been widely documented, however, there are a number of studies that have reported the effect of CBD in pharmacological models of AD. These studies have described anti-inflammatory and neuroprotective effects of CBD.

"A Pioneering Clinical Trial Investigate if Medical Cannabis Can Treat the Tics in Tourette Syndrome"?

A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.

The trial is the first of its kind in Australia and will take place at Wesley Medical Research in Brisbane led by Chief Investigator and neuropsychiatrist Dr Philip Mosley. 

Participants will complete two periods of treatment with either a medicinal cannabis drug or a placebo, with both investigators and participants unaware of treatment status until the end of the trial.

Participants in the clinical trial at Wesley Medical Research will complete two six-week "crossover" periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.

"The Antiemetic effect of THC in patients receiving cancer chemotherapy"

Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents.

In a study published in 16 Oct 1975 from 'The New England Journal of Medicine', oral THC (delta-9-tetrahydrocannabinol) was compared with placebo in a controlled, randomized, "double-blind" experiment. 


All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. 

For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo. No patient vomited while experiencing a subjective "high." 

Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducing vomiting caused by chemotherapeutic agents.

"Just realize that this study is from 1975... but still we searching for evidence"

Source: https://www.nejm.org